Solorank.ai
Login

Cached score snapshot

US.CRL · Charles River Laboratories

110分制 50/110；5D動能v2 5/50；排序分 55/160

Back to ranking Open volume snapshot
Ranking score 55/160
Main score 50/110
5D momentum v2 5/50
Rank #273
Setup grade F 21.8

Score breakdown

避免

Elevated twelvedata

Score and price trend

F 21.8 Elevated risk

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 04-23 07-24 08-06 08-19 08-31 $136.67$205.73$274.80 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.819 · anchors 120 +0.98% -1.08% / +3.45% 62% 3% Actual +4.37% · vs median +3.39% · inside 25-75 band
30D observation +6.92% -0.59% / +14.20% 73.2% 14.8% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.05% -1.05% / +3.87% 64.4% 3.8% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-04-23 → 2026-08-31 · 351 archived points · 2 Improving turn signal · 5 Deteriorating signal · 1 Exit review signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 55
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 50/110 (避免)
5D momentum v2 5/50 (弱)
Score with momentum v2 55/160 (低排序)
Risk level Elevated

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 221.2165
ma50 192.7406
close 219.7
prevClose 224.35
avgVolume20 916016
volumeRatio 1.04
changePercent -2.07

Metrics snapshot

close 219.7
volume 953019
changePercent -2.07

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 50/110
Main rating 避免
5D momentum v2 5/50
Score with momentum v2 55/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 1.5/5 · 較差
Dimension score 1.5/5
Dimension grade 較差

Sub-items

pbPoints 0.2
pePoints 0
epsPoints 0
roePoints 0
debtPoints 0.4
marginPoints 0
turnoverUsdM 209.3783
volumePoints 0.5
revenuePoints 0
dividendPoints 0
marketCapPoints 0.4

資金流 — 10/20 · 較差
Dimension score 10/20
Dimension grade 較差

Sub-items

cmfPoints 4
mfiPoints 1.6
obvPoints 1.6
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.CRL
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 6.2/15 · 較差
Dimension score 6.2/15
Dimension grade 較差

Sub-items

vix

score 1.8

details

source twelvedata+fred
vixClose 18.77

trend

score 0.8

details

qqq

ma20 716.1175
ma50 719.011
name QQQ
close 696.06
points 0.4

spy

ma20 744.7885
ma50 744.5456
name SPY
close 742.09
points 0.4
source twelvedata+fred
atrPct 3.7958
atrPoints 2
cciPoints 1.6
vixPoints 1.8
marketTrendPoints 0.8

催化劑 — 6/20 · 較差
Dimension score 6/20
Dimension grade 較差

Sub-items

catalyst

score 6

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 1
catalystPoints 6

風險管理 — 5.7/10 · 較差
Dimension score 5.7/10
Dimension grade 較差

Sub-items

position

score 1.1

details

atrPct 3.7958
turnoverUsdM 209.3783
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.CRL
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 203.0214

strength_details

ma_score 1.5
atr_score 1
rsi_score 1
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 7.6
take_profit_price 232.3757
target_multiplier 1.6
technical_strength 1.42
take_profit_percent 5.8
positionPoints 1.1
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 7.5915
diversificationPoints 2

技術信號 — 16.6/30 · 較差
Dimension score 16.6/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 1.5
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1.5
vcp_reason 跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N

vcp_metrics

up_days 3
vol_ref 851090
down_days 6
vcp_ready false
above_ma50 true
avg_vol_10 806230
avg_vol_20 926870
avg_vol_30 851090
range_pct_10 0.0886
range_pct_20 0.2683
range_pct_30 0.2683
up_expand_ok true
lookback_used 59
near_20d_high false
contraction_ok false
down_shrink_ok true
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 0.9473
dist_to_20d_high 0.0763
down_shrink_days 3
breakout_level_20d 237.86
vcp_breakout_confirm false
contraction_ratio_10_30 0.3303
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.6

sentimentData

raw {"id":140958949,"url":"https://finnhub.io/api/news?id=83f112067729714753fb3875eb02ff2510b1f1356cc8d88c75257607a7431130","image":"","source":"Fintel","related":"CRL","summary":"","category":"company","datetime":1784548900,"headline":"CLSA Downgrades Charles River Laboratories International (CRL)"}, {"id":140934681,"url":"https://finnhub.io/api/news?id=0d7e83486c89d222dc3769dce586a3573c6f9a41f644d03e12aeac2bacb11eca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.","category":"company","datetime":1784304002,"headline":"What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?"}, {"id":140929134,"url":"https://finnhub.io/api/news?id=c3039391183d169d5c29150bc2a1a61ab957c8d50c62c553e1522fc8ecb05e8e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International (CRL) has drawn fresh investor attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, an off the shelf CAR-iNKT cell therapy program. See our latest analysis for Charles River Laboratories International. The collaboration news comes as Charles River Laboratories International trades at US$229.16, with a 30 day share price return of 24.01% and a 1 year total shareholder...","category":"company","datetime":1784262794,"headline":"Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?"}, {"id":140919042,"url":"https://finnhub.io/api/news?id=0c3cc32b0ac58d975eb0f821b41df81be9995c1abaf3bddd6b064d60b4e23d7d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"In July 2026, Arovella Therapeutics announced a collaboration with Charles River Laboratories International to provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing in support of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. The partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...","category":"company","datetime":1784196692,"headline":"Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?"}, {"id":140900063,"url":"https://finnhub.io/api/news?id=082e4e979ef332876504bc052995c8027281c32622380f6499f371a90f1f3c83","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.","category":"company","datetime":1784045405,"headline":"Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?"}, {"id":140807120,"url":"https://finnhub.io/api/news?id=0be1ab71065229cd12c18938420ca1ea0de7dd33e244110c4477fa182d790fb8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International, Inc. (NYSE:CRL) is one of the top stocks to buy according to Ariel Investments. On June 17, Morgan Stanley upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to an Overweight from Equalweight and raised the price target to $220 from $185. The research firm remains bullish on the company’s long-term prospects and […]","category":"company","datetime":1783172190,"headline":"Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?"}, {"id":140794225,"url":"https://finnhub.io/api/news?id=87afbbdfa3cf90f6fa9c2f1606b8e4e2815a41965d06fb3a2e23ca6b6f724d0d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P 500 has gained 9.3%.","category":"company","datetime":1783019304,"headline":"3 Reasons to Avoid CRL and 1 Stock to Buy Instead"}, {"id":140782807,"url":"https://finnhub.io/api/news?id=67d747b0e4de7ac62347615064d2cb439961b24f91a7a1a938f941d01938ecdb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"LH vs. CRL: Which Stock Is the Better Value Option?","category":"company","datetime":1782920405,"headline":"LH or CRL: Which Is the Better Value Stock Right Now?"}
raw_source {"id":140961419,"url":"https://finnhub.io/api/news?id=d637934a79a18f0fbb5960f741f6b23332bad7d4c8cea1f1b5a337a6b4684e21","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.","category":"company","datetime":1784565301,"headline":"What's going on in today's session: S&P500 movers"}, {"id":140964977,"url":"https://finnhub.io/api/news?id=91757da27d905adfa467e3b6268971b5d3137a3598c3aac6b41924b8129c733e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.","category":"company","datetime":1784562231,"headline":"Charles River Laboratories Earnings Preview: What to Expect"}, {"id":140958949,"url":"https://finnhub.io/api/news?id=83f112067729714753fb3875eb02ff2510b1f1356cc8d88c75257607a7431130","image":"","source":"Fintel","related":"CRL","summary":"","category":"company","datetime":1784548900,"headline":"CLSA Downgrades Charles River Laboratories International (CRL)"}, {"id":140934681,"url":"https://finnhub.io/api/news?id=0d7e83486c89d222dc3769dce586a3573c6f9a41f644d03e12aeac2bacb11eca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.","category":"company","datetime":1784304002,"headline":"What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?"}, {"id":140929134,"url":"https://finnhub.io/api/news?id=c3039391183d169d5c29150bc2a1a61ab957c8d50c62c553e1522fc8ecb05e8e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International (CRL) has drawn fresh investor attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, an off the shelf CAR-iNKT cell therapy program. See our latest analysis for Charles River Laboratories International. The collaboration news comes as Charles River Laboratories International trades at US$229.16, with a 30 day share price return of 24.01% and a 1 year total shareholder...","category":"company","datetime":1784262794,"headline":"Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?"}, {"id":140922751,"url":"https://finnhub.io/api/news?id=064695c2c7c73e8c795a57647a68b4874cbf622ad91f18be92ec15c915686b53","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.","category":"company","datetime":1784217000,"headline":"Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market"}, {"id":140921387,"url":"https://finnhub.io/api/news?id=354c75e1ea8127553c95abb7c927110b41672229afc0a5e5075f2b7293626180","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.","category":"company","datetime":1784209202,"headline":"Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?"}, {"id":140919042,"url":"https://finnhub.io/api/news?id=0c3cc32b0ac58d975eb0f821b41df81be9995c1abaf3bddd6b064d60b4e23d7d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"In July 2026, Arovella Therapeutics announced a collaboration with Charles River Laboratories International to provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing in support of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. The partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...","category":"company","datetime":1784196692,"headline":"Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?"}, {"id":140908618,"url":"https://finnhub.io/api/news?id=a4686923cf2ae0bccc68715c5dd217f0a93027deba81200c594746b5ef65c208","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., July 15, 2026--Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call","category":"company","datetime":1784116800,"headline":"Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call"}, {"id":140906904,"url":"https://finnhub.io/api/news?id=26ba1d6140c24baf0244169fcb31d4e7b0736e23a09e8f714aca89acedb29364","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Opportunities span cytotoxicity, phenotypic and morphological assays, flow cytometry, and pharma and biotech demand. Asia-Pacific and Europe expansion, rare-disease models, single-cell services, and patient-derived and cardiac organoid platforms offer further potential. Cell-Based Assay Services for Preclinical Use Only Market Cell-Based Assay Services for Preclinical Use Only Market Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The \"Cell-Based Assay Services for Preclinical Use Only Global Market O","category":"company","datetime":1784107500,"headline":"Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released — Profiles Charles River, Labcorp, Eurofins and Evotec"}, {"id":140900063,"url":"https://finnhub.io/api/news?id=082e4e979ef332876504bc052995c8027281c32622380f6499f371a90f1f3c83","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.","category":"company","datetime":1784045405,"headline":"Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?"}, {"id":140885104,"url":"https://finnhub.io/api/news?id=fd0b1d464794cb1451526eb0971ba78dc64e37b2409910a9701810fb2f4d9d7b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., July 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA app","category":"company","datetime":1783944000,"headline":"Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches"}, {"id":140886507,"url":"https://finnhub.io/api/news?id=a8b2c8f3e5e344f2a19f19bcb2204a6733a8d0ebc0ff3860ce7fd67951f1bc98","image":"https://cdn.benzinga.com/files/images/story/2026/07/13/Beijing--China---June-4--2023-Keysight-S.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.","category":"company","datetime":1783930266,"headline":"Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday"}, {"id":140892086,"url":"https://finnhub.io/api/news?id=eebeaa97f43d4d52fa7c0a3f4e664b6419720762ccd693470e58e358003eafb6","image":"","source":"Benzinga","related":"CRL","summary":"Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $192 to $230.","category":"company","datetime":1783926070,"headline":"Mizuho Maintains Neutral on Charles River, Raises Price Target to $230"}, {"id":140856250,"url":"https://finnhub.io/api/news?id=b9f7a3fee30a908a0206951371fbb4d8ce5eb3f8f2dac600d176f8a49f8d557a","image":"","source":"Benzinga","related":"CRL","summary":"Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $220 to $260.","category":"company","datetime":1783600751,"headline":"Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $260"}, {"id":140844609,"url":"https://finnhub.io/api/news?id=06debdbe96e5a3379434f0d812c343f6aedc7cf9a24b24158b5f6af43a5df122","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"ICLR is tapping CRO demand, AI workflows and wider trial access, but uneven revenue trends and margin resets keep its earnings recovery in focus.","category":"company","datetime":1783534140,"headline":"ICON Stock and the CRO Trends Shaping Its Next Growth Phase"}, {"id":140831666,"url":"https://finnhub.io/api/news?id=b42db579b28559beb0c3dd7036e41c5bf5256c1ebd275e54eaa52f4f1cd19a5a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.","category":"company","datetime":1783432320,"headline":"Medpace Growth Trends Show How CRO Demand Is Shifting in 2026"}, {"id":140829250,"url":"https://finnhub.io/api/news?id=376a5f774e3a7b2329a07adfaae7e4c5cf120d607ca50f7367fc06a8aa4cda40","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.","category":"company","datetime":1783424272,"headline":"3 Overrated Stocks We’re Skeptical Of"}, {"id":140821257,"url":"https://finnhub.io/api/news?id=965c970ee9bc1c880a7ae424ce53bb3ac5e36a3c41f0c0a4849e290c54a19678","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.","category":"company","datetime":1783346400,"headline":"Medpace Stock Outlook Turns on Backlog Quality and Cancellations"}, {"id":140807120,"url":"https://finnhub.io/api/news?id=0be1ab71065229cd12c18938420ca1ea0de7dd33e244110c4477fa182d790fb8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International, Inc. (NYSE:CRL) is one of the top stocks to buy according to Ariel Investments. On June 17, Morgan Stanley upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to an Overweight from Equalweight and raised the price target to $220 from $185. The research firm remains bullish on the company’s long-term prospects and […]","category":"company","datetime":1783172190,"headline":"Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?"}, {"id":140794225,"url":"https://finnhub.io/api/news?id=87afbbdfa3cf90f6fa9c2f1606b8e4e2815a41965d06fb3a2e23ca6b6f724d0d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P 500 has gained 9.3%.","category":"company","datetime":1783019304,"headline":"3 Reasons to Avoid CRL and 1 Stock to Buy Instead"}, {"id":140782807,"url":"https://finnhub.io/api/news?id=67d747b0e4de7ac62347615064d2cb439961b24f91a7a1a938f941d01938ecdb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"LH vs. CRL: Which Stock Is the Better Value Option?","category":"company","datetime":1782920405,"headline":"LH or CRL: Which Is the Better Value Stock Right Now?"}, {"id":140780947,"url":"https://finnhub.io/api/news?id=a7642c45e1a86a3113777b94e638cc282a04bf08bf074521d37c7dba7c1e84a8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River leans on RMS strength, CRADL adoption and portfolio moves. Can these offset soft biopharma demand and currency headwinds?","category":"company","datetime":1782912480,"headline":"Is This the Right Time to Hold CRL Stock in Your Portfolio?"}, {"id":140781615,"url":"https://finnhub.io/api/news?id=a41b497352b243f30385a2d53aefb1bce180e1468e1ef5bef606c5f068d620db","image":"https://image.cnbcfm.com/api/v1/image/108328987-17828552841782855282-46874781825-1080pnbcnews.jpg?v=1782855283&w=1920&h=1080","source":"CNBC","related":"CRL","summary":"CNBC's Angelica Peebles to talk Anthropic's new healthcare offering.","category":"company","datetime":1782841349,"headline":"Anthropic launches Claude Science"}, {"id":140769645,"url":"https://finnhub.io/api/news?id=42ebca08725488bcaeb7da6f8764e5eef18c6f7dac01e2607f09e5a0cc3cdc75","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2228869477/image_2228869477.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"CRL","summary":"U.S. equity markets were mixed this week, with weakness in growth and technology offset by strength in defensive and health care sectors. ","category":"company","datetime":1782780900,"headline":"ValuEngine Weekly Market Summary And Commentary"}, {"id":140766943,"url":"https://finnhub.io/api/news?id=a194cc7fdd8513472493cedb2a6591abb4996822621a17b81ae2a5615648e3ed","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Is CRL a good stock to buy? We came across a bullish thesis on Charles River Laboratories International, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CRL. Charles River Laboratories International, Inc.’s share was trading at $202.10 as of June 24th. CRL’s trailing and forward P/E were 25.07 and 18.15 respectively […]","category":"company","datetime":1782763617,"headline":"Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?"}, {"id":140781757,"url":"https://finnhub.io/api/news?id=5baed29654721b5d98fe3ce501ae03081ebb89e584dc62b245c3de70b534c11e","image":"https://image.cnbcfm.com/api/v1/image/108262197-1770323920909-gettyimages-2260105869-bb1_2632_uxvikxrq.jpeg?v=1782775477&w=1920&h=1080","source":"CNBC","related":"CRL","summary":"The Dow rose more than 300 points on Monday to post its first close above 52,000. Alphabet, a new addition to the 30-stock index, jumped almost 5%.","category":"company","datetime":1782760725,"headline":"Tuesday's big stock stories: What’s likely to move the market in the next trading session"}, {"id":140736422,"url":"https://finnhub.io/api/news?id=0670f579dfac7d1206e11eea64d3f7d776cb1650aed7eb2cdea372d7d40188d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"In June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab drug discovery platform. This collaboration ties Charles River more closely into Lilly’s Catalyze360 ecosystem, potentially deepening its role in data-rich, AI-enhanced preclinical research workflows. We’ll now examine how Charles River’s deeper integration into Lilly’s AI-driven...","category":"company","datetime":1782482876,"headline":"Is Charles River (CRL) Quietly Redefining Its Moat Through Lilly’s AI-Driven TuneLab Collaboration?"}, {"id":140714727,"url":"https://finnhub.io/api/news?id=59c07858fec985216968038954f075d71be234136bbdfed5a88fbee8fee74872","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"CRL","summary":"Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.","category":"company","datetime":1782318901,"headline":"Uncover the latest developments among S&P500 stocks in today's session."}, {"id":140696594,"url":"https://finnhub.io/api/news?id=edd7ed3ee1e90eebfe7f95d1e59f993581067dae696dc8b6dfdd9564cea747f8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.","category":"company","datetime":1782165884,"headline":"Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?"}, {"id":140695225,"url":"https://finnhub.io/api/news?id=153a1b1fc1d97bcc3a493b60600e8f222309b069e55eefc165f401135250e1e2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Despite underperforming its industry peers over the past year, analysts remain highly bullish on Charles River Laboratories' long-term prospects.","category":"company","datetime":1782130362,"headline":"How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 31
discarded_article_count 20
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 1.5 5/110 30% 1.5
資金流 10 20/110 50% 10
市場環境 6.2 15/110 41.33% 6.2
催化劑 6 20/110 30% 6
風險管理 5.7 10/110 57% 5.7
技術信號 16.6 30/110 55.33% 16.6
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 5/50
ret_5d -0.0437
max_score 50
max_total 50
raw_total 5
vcp_bonus 0
vol_ratio 1.0282
ret_points 0
vol_points 2
range_ratio 0.6316
volat_points 0
day_range_pct 0.0241
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Elevated
reason risk management score >= 5/10

position

score 1.1

details

atrPct 3.7958
turnoverUsdM 209.3783
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.CRL
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 203.0214

strength_details

ma_score 1.5
atr_score 1
rsi_score 1
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 7.6
take_profit_price 232.3757
target_multiplier 1.6
technical_strength 1.42
take_profit_percent 5.8
positionPoints 1.1
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 7.5915
diversificationPoints 2

Calculation audit log

基本面分析總分: 1.5/5分
資金流分析總分: 10/20分
市場環境分析總分: 6.2/15分
催化劑分析: 6/20分
風險管理總分: 5.7/10分
技術信號分析總分: 16.6/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 85.71
atr
atr 8.3393
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.8
cci
rule Cursor_18.24 CCI bands
level 弱勢
score 4
value -6.6
cmf
rule Cursor_18.24 CMF bands
level 強累積
score 10
value 0.3097
kdj
d 55.1
j 7.6
k 39.27
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 45.7
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 4
trend 弱勢
value 5191881
recentSlope -251881.9
previousSlope 846040
rsi
value 42.96
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 236.2619
position SAR喺價上
distancePct 7.54
previousTrend 下降
ma50
value 192.7406
macd
macd 9.9069
trend 中性偏多
signal 12.0585
histogram -2.1517
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 220.4976
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.04
score 6
avgVolume 916016
currentVolume 953019
derived
ma20 221.2165
ma50 192.7406
prevClose 224.35
avgVolume10 838342
avgVolume20 916016
changePercent -2.07
avgVolumeForScore 916016
ma_cross
ma20 221.2165
ma50 192.7406
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 219.4815
prevMa50 191.9812
spreadPct 14.77
isVolumeBreakout false
bollinger
lower 192.2099
upper 250.2231
position 中間
rsi_short
value 12.97
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.04

Raw calculation JSON

 
{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.795766954938553,
        "turnoverUsdM": 209.3782743,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 203.0214,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 7.6,
      "take_profit_price": 232.3757,
      "target_multiplier": 1.6,
      "technical_strength": 1.42,
      "take_profit_percent": 5.8
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 7.591533909877106,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 55,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 221.2165,
    "ma50": 192.7406,
    "close": 219.7,
    "prevClose": 224.35,
    "avgVolume20": 916016,
    "volumeRatio": 1.04,
    "changePercent": -2.07
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": -0.04374319912948865,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 1.0282121548868774,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.6315786931712591,
      "volat_points": 0,
      "day_range_pct": 0.02407828857532996,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 55,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 6.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 41.33,
        "contribution": 6.2
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 5.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 57,
        "contribution": 5.7
      },
      {
        "raw": 16.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 55.33,
        "contribution": 16.6
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 50,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 6.2/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 5.7/10分",
      "技術信號分析總分: 16.6/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 1.5,
      "資金流": 10,
      "市場環境": 6.2,
      "情緒分析": 4,
      "技術信號": 16.6,
      "風險管理": 5.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 209.3782743,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 4,
          "mfiPoints": 1.6,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.77
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.11750425,
                "ma50": 719.0110022000002,
                "name": "QQQ",
                "close": 696.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 744.7885068500001,
                "ma50": 744.54560184,
                "name": "SPY",
                "close": 742.090027,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.795766954938553,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140958949,
                "url": "https://finnhub.io/api/news?id=83f112067729714753fb3875eb02ff2510b1f1356cc8d88c75257607a7431130",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1784548900,
                "headline": "CLSA Downgrades Charles River Laboratories International (CRL)"
              },
              {
                "id": 140934681,
                "url": "https://finnhub.io/api/news?id=0d7e83486c89d222dc3769dce586a3573c6f9a41f644d03e12aeac2bacb11eca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1784304002,
                "headline": "What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?"
              },
              {
                "id": 140929134,
                "url": "https://finnhub.io/api/news?id=c3039391183d169d5c29150bc2a1a61ab957c8d50c62c553e1522fc8ecb05e8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (CRL) has drawn fresh investor attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, an off the shelf CAR-iNKT cell therapy program. See our latest analysis for Charles River Laboratories International. The collaboration news comes as Charles River Laboratories International trades at US$229.16, with a 30 day share price return of 24.01% and a 1 year total shareholder...",
                "category": "company",
                "datetime": 1784262794,
                "headline": "Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?"
              },
              {
                "id": 140919042,
                "url": "https://finnhub.io/api/news?id=0c3cc32b0ac58d975eb0f821b41df81be9995c1abaf3bddd6b064d60b4e23d7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "In July 2026, Arovella Therapeutics announced a collaboration with Charles River Laboratories International to provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing in support of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. The partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...",
                "category": "company",
                "datetime": 1784196692,
                "headline": "Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?"
              },
              {
                "id": 140900063,
                "url": "https://finnhub.io/api/news?id=082e4e979ef332876504bc052995c8027281c32622380f6499f371a90f1f3c83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784045405,
                "headline": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140807120,
                "url": "https://finnhub.io/api/news?id=0be1ab71065229cd12c18938420ca1ea0de7dd33e244110c4477fa182d790fb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) is one of the top stocks to buy according to Ariel Investments. On June 17, Morgan Stanley upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to an Overweight from Equalweight and raised the price target to $220 from $185. The research firm remains bullish on the company’s long-term prospects and […]",
                "category": "company",
                "datetime": 1783172190,
                "headline": "Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?"
              },
              {
                "id": 140794225,
                "url": "https://finnhub.io/api/news?id=87afbbdfa3cf90f6fa9c2f1606b8e4e2815a41965d06fb3a2e23ca6b6f724d0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P 500 has gained 9.3%.",
                "category": "company",
                "datetime": 1783019304,
                "headline": "3 Reasons to Avoid CRL and 1 Stock to Buy Instead"
              },
              {
                "id": 140782807,
                "url": "https://finnhub.io/api/news?id=67d747b0e4de7ac62347615064d2cb439961b24f91a7a1a938f941d01938ecdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "LH vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782920405,
                "headline": "LH or CRL: Which Is the Better Value Stock Right Now?"
              }
            ],
            "raw_source": [
              {
                "id": 140961419,
                "url": "https://finnhub.io/api/news?id=d637934a79a18f0fbb5960f741f6b23332bad7d4c8cea1f1b5a337a6b4684e21",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1784565301,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 140964977,
                "url": "https://finnhub.io/api/news?id=91757da27d905adfa467e3b6268971b5d3137a3598c3aac6b41924b8129c733e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
                "category": "company",
                "datetime": 1784562231,
                "headline": "Charles River Laboratories Earnings Preview: What to Expect"
              },
              {
                "id": 140958949,
                "url": "https://finnhub.io/api/news?id=83f112067729714753fb3875eb02ff2510b1f1356cc8d88c75257607a7431130",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1784548900,
                "headline": "CLSA Downgrades Charles River Laboratories International (CRL)"
              },
              {
                "id": 140934681,
                "url": "https://finnhub.io/api/news?id=0d7e83486c89d222dc3769dce586a3573c6f9a41f644d03e12aeac2bacb11eca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1784304002,
                "headline": "What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?"
              },
              {
                "id": 140929134,
                "url": "https://finnhub.io/api/news?id=c3039391183d169d5c29150bc2a1a61ab957c8d50c62c553e1522fc8ecb05e8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (CRL) has drawn fresh investor attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, an off the shelf CAR-iNKT cell therapy program. See our latest analysis for Charles River Laboratories International. The collaboration news comes as Charles River Laboratories International trades at US$229.16, with a 30 day share price return of 24.01% and a 1 year total shareholder...",
                "category": "company",
                "datetime": 1784262794,
                "headline": "Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?"
              },
              {
                "id": 140922751,
                "url": "https://finnhub.io/api/news?id=064695c2c7c73e8c795a57647a68b4874cbf622ad91f18be92ec15c915686b53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.",
                "category": "company",
                "datetime": 1784217000,
                "headline": "Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market"
              },
              {
                "id": 140921387,
                "url": "https://finnhub.io/api/news?id=354c75e1ea8127553c95abb7c927110b41672229afc0a5e5075f2b7293626180",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1784209202,
                "headline": "Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 140919042,
                "url": "https://finnhub.io/api/news?id=0c3cc32b0ac58d975eb0f821b41df81be9995c1abaf3bddd6b064d60b4e23d7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "In July 2026, Arovella Therapeutics announced a collaboration with Charles River Laboratories International to provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing in support of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. The partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...",
                "category": "company",
                "datetime": 1784196692,
                "headline": "Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?"
              },
              {
                "id": 140908618,
                "url": "https://finnhub.io/api/news?id=a4686923cf2ae0bccc68715c5dd217f0a93027deba81200c594746b5ef65c208",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., July 15, 2026--Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call",
                "category": "company",
                "datetime": 1784116800,
                "headline": "Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call"
              },
              {
                "id": 140906904,
                "url": "https://finnhub.io/api/news?id=26ba1d6140c24baf0244169fcb31d4e7b0736e23a09e8f714aca89acedb29364",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities span cytotoxicity, phenotypic and morphological assays, flow cytometry, and pharma and biotech demand. Asia-Pacific and Europe expansion, rare-disease models, single-cell services, and patient-derived and cardiac organoid platforms offer further potential. Cell-Based Assay Services for Preclinical Use Only Market Cell-Based Assay Services for Preclinical Use Only Market Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The \"Cell-Based Assay Services for Preclinical Use Only Global Market O",
                "category": "company",
                "datetime": 1784107500,
                "headline": "Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released — Profiles Charles River, Labcorp, Eurofins and Evotec"
              },
              {
                "id": 140900063,
                "url": "https://finnhub.io/api/news?id=082e4e979ef332876504bc052995c8027281c32622380f6499f371a90f1f3c83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784045405,
                "headline": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140885104,
                "url": "https://finnhub.io/api/news?id=fd0b1d464794cb1451526eb0971ba78dc64e37b2409910a9701810fb2f4d9d7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., July 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA app",
                "category": "company",
                "datetime": 1783944000,
                "headline": "Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches"
              },
              {
                "id": 140886507,
                "url": "https://finnhub.io/api/news?id=a8b2c8f3e5e344f2a19f19bcb2204a6733a8d0ebc0ff3860ce7fd67951f1bc98",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Beijing--China---June-4--2023-Keysight-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.",
                "category": "company",
                "datetime": 1783930266,
                "headline": "Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday"
              },
              {
                "id": 140892086,
                "url": "https://finnhub.io/api/news?id=eebeaa97f43d4d52fa7c0a3f4e664b6419720762ccd693470e58e358003eafb6",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Mizuho  analyst Ann Hynes   maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $192 to $230.",
                "category": "company",
                "datetime": 1783926070,
                "headline": "Mizuho Maintains Neutral on Charles River, Raises Price Target to $230"
              },
              {
                "id": 140856250,
                "url": "https://finnhub.io/api/news?id=b9f7a3fee30a908a0206951371fbb4d8ce5eb3f8f2dac600d176f8a49f8d557a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Morgan Stanley  analyst Ricky Goldwasser   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $220 to $260.",
                "category": "company",
                "datetime": 1783600751,
                "headline": "Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $260"
              },
              {
                "id": 140844609,
                "url": "https://finnhub.io/api/news?id=06debdbe96e5a3379434f0d812c343f6aedc7cf9a24b24158b5f6af43a5df122",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "ICLR is tapping CRO demand, AI workflows and wider trial access, but uneven revenue trends and margin resets keep its earnings recovery in focus.",
                "category": "company",
                "datetime": 1783534140,
                "headline": "ICON Stock and the CRO Trends Shaping Its Next Growth Phase"
              },
              {
                "id": 140831666,
                "url": "https://finnhub.io/api/news?id=b42db579b28559beb0c3dd7036e41c5bf5256c1ebd275e54eaa52f4f1cd19a5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.",
                "category": "company",
                "datetime": 1783432320,
                "headline": "Medpace Growth Trends Show How CRO Demand Is Shifting in 2026"
              },
              {
                "id": 140829250,
                "url": "https://finnhub.io/api/news?id=376a5f774e3a7b2329a07adfaae7e4c5cf120d607ca50f7367fc06a8aa4cda40",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
                "category": "company",
                "datetime": 1783424272,
                "headline": "3 Overrated  Stocks We’re Skeptical Of"
              },
              {
                "id": 140821257,
                "url": "https://finnhub.io/api/news?id=965c970ee9bc1c880a7ae424ce53bb3ac5e36a3c41f0c0a4849e290c54a19678",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.",
                "category": "company",
                "datetime": 1783346400,
                "headline": "Medpace Stock Outlook Turns on Backlog Quality and Cancellations"
              },
              {
                "id": 140807120,
                "url": "https://finnhub.io/api/news?id=0be1ab71065229cd12c18938420ca1ea0de7dd33e244110c4477fa182d790fb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) is one of the top stocks to buy according to Ariel Investments. On June 17, Morgan Stanley upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to an Overweight from Equalweight and raised the price target to $220 from $185. The research firm remains bullish on the company’s long-term prospects and […]",
                "category": "company",
                "datetime": 1783172190,
                "headline": "Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?"
              },
              {
                "id": 140794225,
                "url": "https://finnhub.io/api/news?id=87afbbdfa3cf90f6fa9c2f1606b8e4e2815a41965d06fb3a2e23ca6b6f724d0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P 500 has gained 9.3%.",
                "category": "company",
                "datetime": 1783019304,
                "headline": "3 Reasons to Avoid CRL and 1 Stock to Buy Instead"
              },
              {
                "id": 140782807,
                "url": "https://finnhub.io/api/news?id=67d747b0e4de7ac62347615064d2cb439961b24f91a7a1a938f941d01938ecdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "LH vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782920405,
                "headline": "LH or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 140780947,
                "url": "https://finnhub.io/api/news?id=a7642c45e1a86a3113777b94e638cc282a04bf08bf074521d37c7dba7c1e84a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River leans on RMS strength, CRADL adoption and portfolio moves. Can these offset soft biopharma demand and currency headwinds?",
                "category": "company",
                "datetime": 1782912480,
                "headline": "Is This the Right Time to Hold CRL Stock in Your Portfolio?"
              },
              {
                "id": 140781615,
                "url": "https://finnhub.io/api/news?id=a41b497352b243f30385a2d53aefb1bce180e1468e1ef5bef606c5f068d620db",
                "image": "https://image.cnbcfm.com/api/v1/image/108328987-17828552841782855282-46874781825-1080pnbcnews.jpg?v=1782855283&w=1920&h=1080",
                "source": "CNBC",
                "related": "CRL",
                "summary": "CNBC's Angelica Peebles to talk Anthropic's new healthcare offering.",
                "category": "company",
                "datetime": 1782841349,
                "headline": "Anthropic launches Claude Science"
              },
              {
                "id": 140769645,
                "url": "https://finnhub.io/api/news?id=42ebca08725488bcaeb7da6f8764e5eef18c6f7dac01e2607f09e5a0cc3cdc75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2228869477/image_2228869477.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "U.S. equity markets were mixed this week, with weakness in growth and technology offset by strength in defensive and health care sectors. ",
                "category": "company",
                "datetime": 1782780900,
                "headline": "ValuEngine Weekly Market Summary And Commentary"
              },
              {
                "id": 140766943,
                "url": "https://finnhub.io/api/news?id=a194cc7fdd8513472493cedb2a6591abb4996822621a17b81ae2a5615648e3ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Is CRL a good stock to buy? We came across a bullish thesis on Charles River Laboratories International, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CRL. Charles River Laboratories International, Inc.’s share was trading at $202.10 as of June 24th. CRL’s trailing and forward P/E were 25.07 and 18.15 respectively […]",
                "category": "company",
                "datetime": 1782763617,
                "headline": "Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?"
              },
              {
                "id": 140781757,
                "url": "https://finnhub.io/api/news?id=5baed29654721b5d98fe3ce501ae03081ebb89e584dc62b245c3de70b534c11e",
                "image": "https://image.cnbcfm.com/api/v1/image/108262197-1770323920909-gettyimages-2260105869-bb1_2632_uxvikxrq.jpeg?v=1782775477&w=1920&h=1080",
                "source": "CNBC",
                "related": "CRL",
                "summary": "The Dow rose more than 300 points on Monday to post its first close above 52,000. Alphabet, a new addition to the 30-stock index, jumped almost 5%.",
                "category": "company",
                "datetime": 1782760725,
                "headline": "Tuesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140736422,
                "url": "https://finnhub.io/api/news?id=0670f579dfac7d1206e11eea64d3f7d776cb1650aed7eb2cdea372d7d40188d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "In June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab drug discovery platform. This collaboration ties Charles River more closely into Lilly’s Catalyze360 ecosystem, potentially deepening its role in data-rich, AI-enhanced preclinical research workflows. We’ll now examine how Charles River’s deeper integration into Lilly’s AI-driven...",
                "category": "company",
                "datetime": 1782482876,
                "headline": "Is Charles River (CRL) Quietly Redefining Its Moat Through Lilly’s AI-Driven TuneLab Collaboration?"
              },
              {
                "id": 140714727,
                "url": "https://finnhub.io/api/news?id=59c07858fec985216968038954f075d71be234136bbdfed5a88fbee8fee74872",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1782318901,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 140696594,
                "url": "https://finnhub.io/api/news?id=edd7ed3ee1e90eebfe7f95d1e59f993581067dae696dc8b6dfdd9564cea747f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.",
                "category": "company",
                "datetime": 1782165884,
                "headline": "Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140695225,
                "url": "https://finnhub.io/api/news?id=153a1b1fc1d97bcc3a493b60600e8f222309b069e55eefc165f401135250e1e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Despite underperforming its industry peers over the past year, analysts remain highly bullish on Charles River Laboratories' long-term prospects.",
                "category": "company",
                "datetime": 1782130362,
                "headline": "How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 31,
            "discarded_article_count": 20
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 16.6,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 851090,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 806230,
              "avg_vol_20": 926870,
              "avg_vol_30": 851090,
              "range_pct_10": 0.08862084660901241,
              "range_pct_20": 0.26827492034592637,
              "range_pct_30": 0.26827492034592637,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9472911207980355,
              "dist_to_20d_high": 0.07634743126208704,
              "down_shrink_days": 3,
              "breakout_level_20d": 237.86,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.3303359348489993
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.795766954938553,
              "turnoverUsdM": 209.3782743,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 203.0214,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 7.6,
            "take_profit_price": 232.3757,
            "target_multiplier": 1.6,
            "technical_strength": 1.42,
            "take_profit_percent": 5.8
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 7.591533909877106,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 8.3393,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.8
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -6.6
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "強累積",
      "score": 10,
      "value": 0.3097
    },
    "kdj": {
      "d": 55.1,
      "j": 7.6,
      "k": 39.27,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 45.7
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 5191881,
      "recentSlope": -251881.9,
      "previousSlope": 846040
    },
    "rsi": 42.96,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 236.2619,
      "position": "SAR喺價上",
      "distancePct": 7.54,
      "previousTrend": "下降"
    },
    "ma50": 192.7406,
    "macd": {
      "macd": 9.906868763840436,
      "trend": "中性偏多",
      "signal": 12.058545973942763,
      "histogram": -2.151677210102328
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 220.4976,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.04,
      "score": 6,
      "avgVolume": 916016,
      "currentVolume": 953019
    },
    "derived": {
      "ma20": 221.2165,
      "ma50": 192.7406,
      "prevClose": 224.35,
      "avgVolume10": 838342,
      "avgVolume20": 916016,
      "changePercent": -2.07,
      "avgVolumeForScore": 916016
    },
    "ma_cross": {
      "ma20": 221.2165,
      "ma50": 192.7406,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 219.4815,
      "prevMa50": 191.9812,
      "spreadPct": 14.77,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 192.2099,
      "upper": 250.2231,
      "position": "中間"
    },
    "rsi_short": 12.97,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.04
    }
  }
}

Raw metrics JSON

 
{
  "close": 219.7,
  "volume": 953019,
  "changePercent": -2.07
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.